Study for Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin

Trial ID or NCT#

NCT02449681

Status

not recruiting iconNOT RECRUITING

Purpose

This phase 2 study is designed to evaluate the safety and activity of TH-4000, a hypoxia-activated prodrug in participants with recurrent or metastatic squamous cell carcinoma of the head and neck or skin.

Official Title

A Phase 2 Study of Tarloxotinib (TH-4000) in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. * Eastern Cooperative Oncology Group (ECOG) performance status 0-2* Confirmed squamous cell carcinoma (SCC) of the head and neck (oropharynx, oral cavity, hypopharynx, or larynx) or skin* For patients with oropharyngeal cancer, p16 status is known or can be determined* Measurable disease according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)* Acceptable laboratory results as indicated by protocol* Acceptable cardiac function as indicated by protocol
Exclusion Criteria:
  1. * Received prior epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy for recurrent or metastatic Squamous Cell Carcinoma (e.g., oral EGFR TKIs such as erlotinib, gefitinib, or afatinib)* Family history of long corrected QT interval (QTc) syndrome* Receiving medication that prolongs QT interval ,with a risk of causing Torsades de Pointes (TdP), unless ECG meets inclusion criteria while on a stable dose of the medication* Family history of long QTc syndrome* Symptomatic central nervous system (CNS) lesions, or CNS lesions that require therapy* Radiation therapy within 2 weeks prior to the first dose of study medication* Major surgery within 4 weeks or minor surgery within 2 weeks prior to the first dose of study medication* Concurrent active malignancy requiring systemic treatment* Any other serious uncontrolled medical disorders or psychological conditions that may interfere with study conduct including but not limited to: clinically significant active infection* Pregnant or breast-feeding
View All Criteria
Show Less

Investigator(s)

A. Dimitrios Colevas, MD
A. Dimitrios Colevas, MD
Medical oncologist, Head and neck specialist, Cutaneous oncology specialist
Professor of Medicine (Oncology) and, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS) and of Radiation Oncology (Radiation Therapy)

Contact us to find out if this trial is right for you.

Contact

CCTO
650-498-7061

View on ClinicalTrials.gov